Ipsen initiates a phase II “Switch maintenance” trial in metastatic castrate-resistant prostate cancer with tasquinimod

This article or press release has no online content. Please download the associated documents for more information.

© Ipsen Pharma, 65 Quai Georges Gorse, 92100 Boulogne-Billancourt, France. All rights reserved. - 2019